

SUBSTITUTE FOR FORM IPC/SB/08 INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT			ATTY DOCKET NO: KOGANTY=4A FIRST INVENTOR: KOGANTY, R. FILING DATE: September 12, 2005 EXAMINER:		SERIAL NO: 10/511,101 ART UNIT: 1643	
U.S. PATENT DOCUMENTS (include at least patentee, patent/pub number and issue date)						
EXAM. INITIAL	ID	DOCUMENT NUMBER	FILING, ISSUE OR PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
/A.H./	AA	4,235,871	11-25-1980	PAPAHADJOPOULOS, et al.		
	AB	4,501,728	02-26-1985	GEHO et al.		
	AC	4,837,028	06-06-1989	ALLEN		
	AD	4,868,155	09-19-1989	DURETTE, et al.		
	AE	5,019,369	05-28-1991	PRESANT, et al.		
	AF	5,019,383	05-28-1991	HOPP		
	AG	5,744,144	04-28-1998	FINN, et al.		
	AH	5,837,249	11-17-1998	HEBER-KATZ, et al.		
	AI	5,871,746	02-16-1999	BOUTILLON, et al.		
	AJ	5,993,823	11-30-1999	BOUTILLON, et al.		
	AK	6,013,779	01-11-2000	WONG, et al.		
	AL	6,015,564	01-18-2000	BOUTILLON, et al.		
	AM	6,344,203	02-05-2002	SANDRIN, et al.		
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)						
EXAM. INITIAL	ID	COUNTRY CODE & DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
/A.H./	AN	WO 93/21211	10-28-1993	LABORATORIOS MENARINI		E
	AO	WO 95/27505	10-19-1995	BIOMIRA, INC.		E
	AP	WO 01/36433	05-25-2001	BIOMIRA, INC.		E
	AQ	WO 02/076485	10-03-2002	BUDZYNSKI		E
	AR	EP 0 093 851	11-16-1983	NEW YORK BLOOD CENTER, INC		E
	AS	EP 0 203 676	12-03-1986	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY		E
	AT	EP 0 230 893	08-05-1987	BRACCO INDUSTRIA CHIMICA		E
EXAMINER /Anne Holleran/				DATE CONSIDERED 08/20/2008		
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.						

* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

SUBSTITUTE FOR FORM IPC/SB/08		ATTY DOCKET NO: KOGANTY=4A		SERIAL NO: 10/511,101		
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		FIRST INVENTOR: KOGANTY, R.				
		FILING DATE: September 12, 2005				
		EXAMINER:		ART UNIT: 1643		
FOREIGN PATENT DOCUMENTS (include at least document number, publication date and country)						
EXAM. INITIAL	ID	COUNTRY CODE & DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	PATENTEE OR APPLICANT	Relevant Passage(s)	T*
/A.H./	AU	EP 0 491 628	06-24-1992	PASTEUR INSTITUTE, et al.		A
↓	AV	EP 0 945 461	09-29-1999	PASTEUR INSTITUTE, et al.		A
↓	AW	EP 1 065 212	01-03-2001	PASTEUR INSTITUTE, et al.		A
↓	AX	EP 1 182 210	02-27-2002	BASTERT, Gunter, et al.		E
OTHER DOCUMENTS (include AUTHOR, title, name of publication, volume, pages & date of publication) Please list in alphabetical order.						
/A.H./	AY	BROSSART, et al., "Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", <u>BLOOD</u> , vol. 93, no. 12, pp. 4309-4317, June 15, 1999.				
↓	AZ	CARMON, et al., "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in D ^b /X β2 Microglobulin (β2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D ^b -β2 Microglobulin Single Chain", <u>INT. J. CANCER</u> , vol. 85, pp. 391-397, 2000.				
↓	BA	DENTON, et al., "Sequential Order of T and B Cell Epitopes Affects Immunogenicity But Not Antibody Recognition of the B Cell Epitope", <u>PEPTIDE RESEARCH</u> , vol. 7, no. 5, pp. 258-264, 1994.				
↓	BB	DIEZ-BARRA, et al., Chemical Abstract, "Solvent-free phase transfer catalysis. Improvements on serine O-alkylation, Database accession no. 127:220955, 1997.				
↓	BC	ENGELMANN, et al., "Identification and Topology of Variant Sequences within Individual Repeat Domains of the Human Epithelial Tumor Mucin MUC1", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 276, no. 30, pp. 27764-27769, July 27, 2001.				
↓	BD	GENDLER, et al., "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas Is Made Up of Tandem Repeats", <u>THE JOURNAL OF BIOLOGICAL CHEMISTRY</u> , vol. 263, no. 26, pp. 12820-12823, September 15, 1988.				
↓	BE	HEUKAMP, et al., "Identification of Three Non-VNTR MUC1-Derived HLA-A*0201-Restricted T-Cell Epitopes that Induce Protective Anti-Tumor Immunity in HLA-A2/K ^b -Transgenic Mice", <u>INT. J. CANCER</u> , vol. 91, pp. 385-392, 2001.				
↓	BF	HILTBOLD, et al., "Naturally Processed Class II Epitope from the Tumor Antigen MUC1 Primes Human CD4 ⁺ T Cells", <u>CANCER RESEARCH</u> , vol. 58, pp. 5066-5070, November 15, 1998.				
↓	BG	KEIL, et al., "Towards the Development of Antitumor Vaccines: A Synthetic Conjugate of a Tumor-Associated MUC1 Glycopeptide Antigen and a Tetanus Toxin Epitope", <u>ANGEW. CHEM. INT. ED.</u> , vol. 40, no. 2, pp. 366-369, 2001.				
EXAMINER		/Anne Holleran/		DATE CONSIDERED 08/20/2008		
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

* "Relevant Passages" column is optional. Put check in "T" column if English translation of entire document included. If English language abstract included, put A in this box. If ref. in English, put "E". If requirement otherwise met, put O.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

SUBSTITUTE FOR FORM IPC/SB/08 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO: KOGANTY=4A	SERIAL NO: 10/511,101
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		FIRST INVENTOR: KOGANTY, R.	
		FILING DATE: September 12, 2005	
		EXAMINER:	ART UNIT: 1643
OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)			
/A.H./	BH	KUDRYASHOV, et al., "Toward optimized carbohydrate-based anticancer vaccines: Epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis ^x conjugates in mice", <u>PNAS</u> , vol. 98, no. 6, pp. 3264-3269, March 13, 2001.	
	BI	MARTINON, et al., "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 149, no. 10, pp. 3416-3422, November 15, 1992.	
	BJ	MEYLAN, et al., "Atom/Fragment Contribution Method for Estimating Octanol-Water Partition Coefficients", <u>JOURNAL OF PHARMACEUTICAL SCIENCES</u> , vol. 84, no. 1, pp. 83-92, January 1995.	
	BK	MÖLLER, et al., "NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3", <u>EUR. J. BIOCHEM.</u> , vol. 269, pp. 144-1455, 2002.	
	BL	MORTARA, et al., "Selection of Virus Variants and Emergence of Virus Escape Mutants after Immunization with an Epitope Vaccine", <u>JOURNAL OF VIROLOGY</u> , vol. 72, no. 2, pp. 1403-1410, February 1998.	
	BM	PETRAKOU, et al., "Epitope Mapping of Anti-MUC1 Mucin Protein Core Monoclonal Antibodies", <u>TUMOR BIOL.</u> , vol. 19(suppl 1), pp. 21-29, 1998.	
	BN	REICHEL, et al., "Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen-T-epitope-lipopeptide conjugate", <u>CHEM. COMMUN.</u> , pp. 2087-2088, 1997.	
	BO	SAUZET, et al., "Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides", <u>VACCINE</u> , vol. 13, no. 14, pp. 1339-1345, 1995.	
	BP	SOARES, et al., "Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection", <u>THE JOURNAL OF IMMUNOLOGY</u> , vol. 166, pp. 6555-6563, 2001.	
	BQ	SPRINGER, Georg F., "T and Tn, General Carcinoma Autoantigens", <u>SCIENCE</u> , vol. 224, pp. 1198-1206, June 15, 1984.	
	BR	TAYLOR-PAPADIMITRIOU, et al., "Molecular aspects of mucins", <u>CANCER REV.</u> , vol. 11-12, pp. 11-24, 1988.	
↓	BS	TOYOKUNI, et al., "Synthetic Vaccines: Synthesis of a Dimeric Tn Antigen-Lipopeptide Conjugate That Elicits Immune Responses against Tn-Expressing Glycoproteins", <u>J. AM. CHEM. SOC.</u> , vol. 116, pp. 395-396, 1994.	
EXAMINER		/Anne Holleran/	DATE CONSIDERED 08/20/2008
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

SUBSTITUTE FOR FORM IPC/SB/08 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO: KOGANTY=4A	SERIAL NO: 10/511,101
INFORMATION DISCLOSURE STATEMENT LIST OF DOCUMENTS CITED BY APPLICANT		FIRST INVENTOR: KOGANTY, R.	
		FILING DATE: September 12, 2005	
		EXAMINER:	ART UNIT: 1643
OTHER DOCUMENTS (include author, title, name of publication, volume, pages and date of publication)			
/A.H./	BT	VITIELLO, et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection", <u>J. CLIN. INVEST.</u> , vol. 95, pp. 341-349, January 1995.	
	BU	VON MENSdorFF-POUILLY, et al., ABSTRACT ONLY, "Human MUC1 mucin: a multifaceted glycoprotein", <u>INT. J. BIOL. MARKERS</u> , vol. 15(4), pp. 343-56, October-December 2000.	
	BV	VON MENSdorFF-POUILLY, et al., "Reactivity of Natural and Induced Human Antibodies to MUC1 Mucin with MUC1 Peptides and N-Acetylgalactosamine (GalNAc) Peptides", <u>INT. J. CANCER</u> , vol. 86, pp. 702-712, 2000.	
	BW	VON MENSdorFF-POUILLY, et al., "Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin", <u>JOURNAL OF CLINICAL ONCOLOGY</u> , vol. 18, no. 3, pp. 574-583, February 2000.	
EXAMINER		/Anne Holleran/	
		DATE CONSIDERED 08/20/2008	
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.			